+86-28-82633987
Synonym name: 8-Methylophiopogonanone B
Catalogue No.: BP0942
Cas No.: 74805-91-7
Formula: C19H20O5
Mol Weight: 328.364
Botanical Source: Ophiopogon japonicus and Polygonum odoratum
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.
For Reference Standard and R&D, Not for Human Use Directly.
Inquire for bulk scale.
HPLC of Methylophiopogonanone B
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
75.9900
3.6820
3.5049
.1304
4.0782
42.2804
Low
90.7446
2.9820
No
No
Yes
No
No
No
0.6
Yes
No
No
No
Methylophiopogonanone B (CAS No.: 74805-91-7) is a high-isodiporoflavone natural product extracted from the root of the traditional Chinese medicinal material Ophiopogon japonicus. In recent years, with the deepening of natural product pharmacology, methyl ophiopogon flavanone B has become a hot topic in research on metabolic diseases such as diabetes due to its remarkable antioxidant capacity and multi-target regulatory effects. Its unique molecular structure gives it multiple biological functions in cell signaling, cytoskeletal reorganization, and metabolic regulation, especially showing potential therapeutic value in modulating the Rho signaling pathway and AMPK-related metabolic pathways. This article will systematically review the chemical properties, plant origins, pharmacological activity, mechanism of action, and druggability evaluation of methyl myopogon flavanone B, exploring its application prospects in diabetes and related diseases.
Methyl Ophiopogon Flavanone B belongs to the isodihydroflavone class of compounds, with a molecular formula of C19H20O6 and a molecular weight of 328.3640. Its structural features include a typical flavanone backbone with methyl substituents, giving it high lipid solubility (LogP = 3.6820), which facilitates membrane penetration and binding to intracellular targets. Its polar surface area (TPSA) is 75.99 Ų, indicating moderate polarity that favors the balance between aqueous and lipid phases. Low water solubility (0.1304 mg/mL) suggests possible solubility limits in vivo, but moderate lipophilic solubility aids cellular absorption.
The physicochemical properties of methyl myrton flavanone B show that its ability to penetrate the blood-brain barrier is relatively low, which may limit its direct effect in the central nervous system, but this also reduces the risk of central nervous system side effects. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. Ames mutagenic test result was 0.6, indicating low genotoxicity risk and meeting safety requirements.
Methyl Ophiopogon flavanone B is mainly extracted from the root of Ophiopogon japonicus. Ophiopogon japonicus is a perennial herbaceous plant of the Liliaceae family, genus Ophiopogon, widely distributed in southern China and East Asia. In traditional Chinese medicine, it is often used to nourish yin, moisten the lungs, and calm the mind. Its rhizomes are rich in various active components, including saponins, polysaccharides, and flavonoids.
Common methods for extracting methyl ophiopogon flavanone B include:
In recent years, the application of supercritical CO2 extraction and molecular blotting technology has further improved the extraction purity and yield of methyl ophiopogon flavanone B, providing technical support for its large-scale production.
The pharmacological activity of methyl Ophiopogon flavanone B mainly lies in antioxidant properties, cytoskeletal reorganization regulation, and metabolic regulation.
As a highly isodihydroflavone, methyl mymapogon flavanone B exhibits significant free radical scavenging ability, effectively inhibiting the generation of reactive oxygen species (ROS) and reducing cellular damage caused by oxidative stress. In vitro experiments have shown that it has good scavenging effects against DPPH free radicals, superoxide anions, and hydroxyl radicals, protecting cells from oxidation-induced apoptosis and inflammatory reactions.
Methyl Ophiopogon Flavanone B can significantly increase GTP-Rho levels, inducing actin cytoskeleton reorganization by activating the Rho signaling pathway, manifesting as dendritic contraction and stress fiber formation. These morphological changes are significant for cell migration, morphological maintenance, and signal transduction, suggesting their potential roles in tissue repair and cell function regulation.
The potential of methyl myptomorphic flavanone B in diabetes treatment is receiving increasing attention. Its targets involve key metabolic enzymes and transport proteins such as AMPK (PRKAA1), SGLT2, and GCK, which can regulate glucose metabolism and energy homeostasis. By activating the AMPK signaling pathway, methyl myphalophalanthanone B promotes the balance of glycolipid metabolism, improves insulin resistance, and lowers blood sugar levels. Additionally, its regulatory effect on PTPN1 (protein tyrosine phosphatase 1B) helps enhance insulin signaling and further exerts anti-diabetic effects.
The biological function of methyl Ophiopogon flavanone B depends on its regulation of multiple signaling pathways, involving cytoskeletal dynamic regulation, metabolic signal transduction, and neuroprotection.
By increasing GTP-Rho activity, methyl Ophiopogon flavanone B regulates the activation state of small GTPases in the Rho family, promoting the polymerization of actin fibers and the formation of stress fibers, thereby affecting cell morphology and migration. This mechanism is of great significance in cell repair, immune regulation, and tumor metastasis.
AMPK is a key regulator of cellular energy metabolism. Methyl Ophiopogon Flavanone B promotes glucose uptake and fatty acid oxidation by activating AMPK (PRKAA1), improving metabolic disorders. This mechanism is especially critical in the treatment of diabetes and metabolic syndrome.
Methyl Maipogon Flavanone B also involves regulation of multiple targets such as SGLT2 (sodium-glucose cotransporter 2), GCK (glucose kinase), PTPN1, MAOA (monoamine oxidase A), and ESR2 (estrogen receptor β), demonstrating its multi-target and multi-pathway synergistic effects. This multi-target mode of action helps improve the broadness and overall efficacy of treatment.
Druggability evaluation of methyl myptogen flavanone B shows it has promising potential for drug development:
In terms of pharmacokinetics, existing studies show that methyl mypon flavanone B is absorbed quickly after oral administration, but its bioavailability is limited by solubility and first-pass effect. Its metabolism mainly occurs through hepatic enzyme systems, with bile being the primary excretion pathway. Future studies are needed to systematically study its metabolic kinetic parameters and distribution characteristics.
Methyl Ophiopogon Flavanone B, as a versatile natural product, has broad clinical application potential, especially excelling in the prevention and treatment of diabetes and its complications. It modulates metabolic pathways through multiple targets, improves insulin sensitivity and energy metabolism, and possesses both antioxidant and cell-protective effects, making it suitable for development as novel antidiabetic drugs or adjuvant therapies.
Additionally, the regulatory effect of methyl Ophiopogon flavanone B on the cytoskeleton suggests its potential application value in tissue repair, anti-inflammation, and neuroprotection. In the future, technologies such as nanocarriers and drug modification can be combined to optimize pharmacokinetic properties and improve targeting and therapeutic efficacy.
However, clinical research on methyl morphopogon flavanone B is still in its early stages and lacks systematic clinical trial data. In the future, clinical evaluation of its pharmacodynamics, safety, and pharmacokinetics should be strengthened to clarify the optimal dosing regimen and indication range. At the same time, in-depth analysis of its mechanism of action and molecular targets will help guide its clinical application and new drug development.
Methyl Ophiopogon Flavanone B, as an important active ingredient in Ophiopogon, demonstrates excellent antioxidant, metabolic regulation, and cytoskeletal remodeling abilities due to its unique chemical structure and multi-target pharmacological effects. Its therapeutic potential in diabetes and related metabolic diseases is becoming increasingly prominent, with a solid foundation for druggability and safety. In the future, through in-depth mechanistic research and clinical validation, methyl ophiopogon flavanone B is expected to become an important candidate molecule in the development of natural product drugs, providing new strategies and ideas for the treatment of diabetes and metabolic diseases.
Shenshuai
Wenjing
Hedandan
